Colin P Bergstrom1, Muhammad S Beg2, Colby Ayers3, Arjun Gupta1, Ian J Neeland4. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Division of Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Lymphotoxin-beta receptor (LTβR) is an immunological protein associated with inflammation, and from preclinical studies is implicated in tumorigenesis. The epidemiological relationships with cancer are unknown, hence this study investigated their associations. METHODS: From a multiethnic population-based cohort, 3,032 participants without a prevalent cancer (a diagnosis prior to or within one year of enrollment) at baseline underwent measurement of plasma LTβR. These participants were followed for incident cancer using the Texas Cancer Registry (TCR). RESULTS: Over a median follow-up of 12.1 years, 178 participants developed incident cancer, of which 30 participants developed incident gastrointestinal (GI) cancer. Median plasma LTβR (1.10 vs. 1.00 ng/mL, P<0.02) levels were higher in individuals with overall incident cancer compared to those without cancer. After adjustments for age, sex, and race/ethnicity, these relationships were no longer significant. When analyses were stratified by cancer type, LTβR was positively associated with GI cancer after adjustments: HR, 95% CI per 1-standard deviation increase in concentration 2.64 (1.23-5.68), P=0.013. LTβR stratified by quartiles was significantly associated temporally with the risk of incident GI cancer, log-rank: P=0.011. The median interval to incident GI cancer diagnosis was 5.9 years. CONCLUSIONS: Increased plasma levels of LTβR are associated with the development of GI cancer. The antecedent findings years prior to a subsequent diagnosis of incident GI cancer suggest a role for LTβR in the pathogenesis of GI cancer. Further studies are needed to determine if LTβR can serve as an immune biomarker for GI cancer, in particular hepatocellular and colorectal cancers. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Lymphotoxin-beta receptor (LTβR) is an immunological protein associated with inflammation, and from preclinical studies is implicated in tumorigenesis. The epidemiological relationships with cancer are unknown, hence this study investigated their associations. METHODS: From a multiethnic population-based cohort, 3,032 participants without a prevalent cancer (a diagnosis prior to or within one year of enrollment) at baseline underwent measurement of plasma LTβR. These participants were followed for incident cancer using the Texas Cancer Registry (TCR). RESULTS: Over a median follow-up of 12.1 years, 178 participants developed incident cancer, of which 30 participants developed incident gastrointestinal (GI) cancer. Median plasma LTβR (1.10 vs. 1.00 ng/mL, P<0.02) levels were higher in individuals with overall incident cancer compared to those without cancer. After adjustments for age, sex, and race/ethnicity, these relationships were no longer significant. When analyses were stratified by cancer type, LTβR was positively associated with GI cancer after adjustments: HR, 95% CI per 1-standard deviation increase in concentration 2.64 (1.23-5.68), P=0.013. LTβR stratified by quartiles was significantly associated temporally with the risk of incident GI cancer, log-rank: P=0.011. The median interval to incident GI cancer diagnosis was 5.9 years. CONCLUSIONS: Increased plasma levels of LTβR are associated with the development of GI cancer. The antecedent findings years prior to a subsequent diagnosis of incident GI cancer suggest a role for LTβR in the pathogenesis of GI cancer. Further studies are needed to determine if LTβR can serve as an immune biomarker for GI cancer, in particular hepatocellular and colorectal cancers. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Xiaolin Hu; Mary A Zimmerman; Kankana Bardhan; Dafeng Yang; Jennifer L Waller; Georgia B Liles; Jeffrey R Lee; Raphael Pollock; Dina Lev; Carl F Ware; Ellen Garber; Veronique Bailly; Jeffrey L Browning; Kebin Liu Journal: Carcinogenesis Date: 2013-01-24 Impact factor: 4.944
Authors: Meira Epplein; Yong-Bing Xiang; Qiuyin Cai; Richard M Peek; Honglan Li; Pelayo Correa; Jing Gao; Jie Wu; Angelika Michel; Michael Pawlita; Wei Zheng; Xiao-Ou Shu Journal: Cancer Causes Control Date: 2013-09-20 Impact factor: 2.506
Authors: Iris Shai; Matthias B Schulze; Joann E Manson; Kathryn M Rexrode; Meir J Stampfer; Christos Mantzoros; Frank B Hu Journal: Diabetes Care Date: 2005-06 Impact factor: 19.112
Authors: Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: P Stopfer; F Obermeier; N Dunger; W Falk; S Farkas; M Janotta; A Möller; D N Männel; T Hehlgans Journal: Clin Exp Immunol Date: 2004-04 Impact factor: 4.330
Authors: Anthony J Scarzello; Qun Jiang; Timothy Back; Hien Dang; Deborah Hodge; Charlotte Hanson; Jeffrey Subleski; Jonathan M Weiss; Jimmy K Stauffer; Jitti Chaisaingmongkol; Siritida Rabibhadana; Mathuros Ruchirawat; John Ortaldo; Xin Wei Wang; Paula S Norris; Carl F Ware; Robert H Wiltrout Journal: Gut Date: 2015-07-23 Impact factor: 23.059